Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells
Science Translational Medicine · 2024
DOI: 10.1126/scitranslmed.adn8388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Luiz Henrique Geraldo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Roundabout Proteins, Signal Transduction, Myeloid Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Roundabout (ROBO) 1 and 2 are transmembrane receptors that bind secreted SLIT ligands through their extracellular domains (ECDs) and signal through their cytoplasmic domains to modulate the cytoskeleton and regulate cell migration, adhesion, and proliferation. SLIT-ROBO signaling regulates pathological ocular neovascularization, which is a major cause of vision loss worldwide, but pharmacological tools to prevent SLIT-ROBO signaling are lacking. Here, we developed human monoclonal antibodies (mAbs) against the ROBO1 and ROBO2 ECDs. One antibody that inhibited in vitro SLIT2 signaling through ROBO1 and ROBO2 (anti-ROBO1/2) also reduced ocular neovascularization in oxygen-induced retinopathy (OIR) and laser-induced corneal neovascularization (CNV) mouse models in vivo. Single-cell RNA sequencing of OIR retinas revealed that antibody treatment affected several cell types relevant to physiological and pathological angiogenesis, including endothelial cells, pericytes, and a heterogeneous population of myeloid cells. mAb treatment improved blood-retina barrier integrity and prevented pathological pericyte activation in OIR. SLIT-ROBO signaling inhibition prevented pathological activation of myeloid cells and increased neuroprotective myeloid populations normally seen in the developing retina. Microglia/infiltrating macrophage–specific ablation of Robo1 and Robo2 or knockout of the downstream effector phosphatidylinositol 3-kinase ( Pik3cg ) encoding PI3Kγ in both OIR and CNV models phenocopied anti-ROBO1/2 treatment, further demonstrating the key role of myeloid cells as drivers of ocular neovascular diseases. ROBO1/2 blocking antibodies may thus provide a promising strategy to combat inflammation in blinding eye diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
- Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06510, USA.
- Université de Paris, INSERM, PARCC, F-75015 Paris, France.
- Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.
- School of Pharmacy, University of Waterloo, Kitchener, Ontario N2G 1C5, Canada.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA.
ORCID-Profile: Luiz Henrique Geraldo, Gaspard Mouthon, Jessica Furtado, Felipe Saceanu Leser, Levi L Blazer, Jarrett J Adams, Sophia Zhang, Lana Zheng, Eric Song, Mark E Robinson, Jean-Leon Thomas, Anne Eichmann
Förderung
- NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Geraldo, L. H., Xu, Y., Mouthon, G., Furtado, J., Leser, F. S., Blazer, L. L., Adams, J. J., Zhang, S., Zheng, L., Song, E., Robinson, M. E., Thomas, J. L., Sidhu, S. S., & Eichmann, A. (2024). Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adn8388
Vancouver
Geraldo LH, Xu Y, Mouthon G, Furtado J, Leser FS, Blazer LL, et al. Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adn8388
BibTeX
@article{Geraldo2024,
author = {Geraldo, Luiz Henrique and Xu, Yunling and Mouthon, Gaspard and Furtado, Jessica and Leser, Felipe Saceanu and Blazer, Levi L and Adams, Jarrett J and Zhang, Sophia and Zheng, Lana and Song, Eric and Robinson, Mark E and Thomas, Jean-Leon and Sidhu, Sachdev S and Eichmann, Anne},
title = {Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells},
journal = {Science Translational Medicine},
year = {2024},
doi = {10.1126/scitranslmed.adn8388}
}
EUVIMED